News Releases
Allon's CEO presenting at BIO Investor Forum
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) President and CEO Gordon McCauley will present an update of the Company’s business progress on Wednesday, October 26 at the 10th Annual BIO Investor Forum in San Francisco attended by public and private equity investors, research analysts, inv... Continue reading
Posted in News Releases
Allon Therapeutics announces completion of patient enrollment in pivotal trial
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that it has successfully achieved the enrollment objective of 300 patients in the phase 2/3 pivotal clinical trial evaluating the Company’s lead neuroprotective drug candidate davunetide as a potential treatment for progressive ... Continue reading
Posted in News Releases
Allon Therapeutics Completes Equity Offering
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC), today announced that it has completed the previously announced public offering of units and common shares resulting in gross proceeds of $4,357,842.50 and a subscription receipt for $1,084,032.50 for a total of $5,441,875 as more particularly ... Continue reading
Posted in News Releases
Allon granted important U.S. patent for preclinical compound AL-408
VANCOUVER, B.C. — Allon Therapeutics Inc. (TSX: NPC) announced today that it has been granted an important United States patent covering the composition of matter for the D-isomer of NAP (davunetide). The D-isomer of davunetide is known as AL-408 in the company’s pipeline. This new patent streng... Continue reading
Posted in News Releases
Allon Therapeutics Amends Terms of Offering and Prices Offering
VANCOUVER, B.C. – Allon Therapeutics Inc. (“Allon Therapeutics” or the “Company”) (TSX – “NPC”) announced today that, further to its press release dated September 14, 2011, that GMP Securities L.P. (the “Lead Agent”), on behalf of a syndicate of agents, including Canaccord Genuity Corp. (togethe... Continue reading
Posted in News Releases